Literature DB >> 21671140

Immunohistochemical study of the angiogenetic network of VEGF, HIF1α, VEGFR-2 and endothelial nitric oxide synthase (eNOS) in human breast cancer.

Maria Kafousi1, Thomas Vrekoussis, Eleftheria Tsentelierou, Kitty Pavlakis, Iordanis Navrozoglou, Vassilios Dousias, Elias Sanidas, Dimitrios Tsiftsis, Vassilios Georgoulias, Efstathios N Stathopoulos.   

Abstract

BACKGROUND: The role of Nitric Oxide (NO) in angiogenesis has not been fully clarified yet. A dual role for NO, either inductive or inhibitory, has been proposed on the basis of different effects that high or low concentrations of NO may exert on the angiogenic process. Additionally, it has been referred that NO may induce VEGF production, while VEGF may induce NO production via up-regulation of the endothelial nitric oxide synthase (eNOS), the two pathways being reverse. The aim of the current study was to investigate the expression of key molecules involved in these opposite pathways in primary breast cancer.
METHODS: Representative tumor samples from 242 patients with early-stage breast cancer (invasive ductal breast carcinomas) were investigated for the expression of VEGF, VEGFR-2, HIF1α, iNOS, and eNOS using immunohistochemistry.
RESULTS: Endothelial NOS was found in 159 cases, VEGF in 131 cases, HIF-1α in 139 cases, VEGFR2 in 185 cases and inducible NOS (iNOS) in 22 cases. There was a significant correlation between the expression of VEGF and VEGFR-2, eNOS and VEGF, eNOS and VEGFR-2, eNOS and HIF1α. No statistically significant correlation was found between iNOS and the rest of the studied molecules.
CONCLUSIONS: In breast cancer cases, the major molecules regulating NO and VEGF production can be co-expressed in the individual carcinomas implying a possibility for the relevant pathways to be active; however appropriate functional experiments remain to be conducted to prove such a hypothesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21671140     DOI: 10.1007/s12253-011-9413-8

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  51 in total

Review 1.  Role of hypoxia-inducible factor-1alpha as a cancer therapy target.

Authors:  Shalini Patiar; Adrian L Harris
Journal:  Endocr Relat Cancer       Date:  2006-12       Impact factor: 5.678

2.  Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src.

Authors:  H He; V J Venema; X Gu; R C Venema; M B Marrero; R B Caldwell
Journal:  J Biol Chem       Date:  1999-08-27       Impact factor: 5.157

3.  Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer.

Authors:  Y Takahashi; S L Tucker; Y Kitadai; A N Koura; C D Bucana; K R Cleary; L M Ellis
Journal:  Arch Surg       Date:  1997-05

4.  Suppression of hypoxia-associated vascular endothelial growth factor gene expression by nitric oxide via cGMP.

Authors:  N Ghiso; R M Rohan; S Amano; R Garland; A P Adamis
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-05       Impact factor: 4.799

5.  High expression of endothelial cell nitric oxide synthase in peritumoral microvessels predicts increased disease-free survival in colorectal cancer.

Authors:  Kirsten Mortensen; Ib Jarle Christensen; Hans Jørgen Nielsen; Ulla Hansen; Lars-Inge Larsson
Journal:  Cancer Lett       Date:  2004-12-08       Impact factor: 8.679

6.  Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer.

Authors:  M M Vleugel; A E Greijer; A Shvarts; P van der Groep; M van Berkel; Y Aarbodem; H van Tinteren; A L Harris; P J van Diest; E van der Wall
Journal:  J Clin Pathol       Date:  2005-02       Impact factor: 3.411

Review 7.  Targeting tumour hypoxia in breast cancer.

Authors:  Manuela Milani; Adrian L Harris
Journal:  Eur J Cancer       Date:  2008-11-05       Impact factor: 9.162

8.  Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer.

Authors:  Yutaka Yamamoto; Mutsuko Ibusuki; Yasuhiro Okumura; Teru Kawasoe; Kazuharu Kai; Kenichi Iyama; Hirotaka Iwase
Journal:  Breast Cancer Res Treat       Date:  2007-09-06       Impact factor: 4.872

9.  Vascular endothelial estrogen receptor alpha is modulated by estrogen status and related to endothelial function and endothelial nitric oxide synthase in healthy women.

Authors:  Kathleen M Gavin; Douglas R Seals; Annemarie E Silver; Kerrie L Moreau
Journal:  J Clin Endocrinol Metab       Date:  2009-06-09       Impact factor: 5.958

Review 10.  Bevacizumab for advanced breast cancer.

Authors:  Tiffany A Traina; Hope S Rugo; Maura Dickler
Journal:  Hematol Oncol Clin North Am       Date:  2007-04       Impact factor: 3.722

View more
  9 in total

Review 1.  Gasotransmitters in the tumor microenvironment: Impacts on cancer chemotherapy (Review).

Authors:  Abbas Salihi; Mohammed A Al-Naqshabandi; Zhikal Omar Khudhur; Zjwan Housein; Harmand A Hama; Ramyar M Abdullah; Bashdar Mahmud Hussen; Twana Alkasalias
Journal:  Mol Med Rep       Date:  2022-05-26       Impact factor: 3.423

Review 2.  Perioperative propofol-paravertebral anesthesia decreases the metastasis and progression of breast cancer.

Authors:  Xiu Chen; Peng Lu; Lin Chen; Su-jin Yang; Hong-Yu Shen; Dan-dan Yu; Xiao-hui Zhang; Shan-liang Zhong; Jian-hua Zhao; Jin-hai Tang
Journal:  Tumour Biol       Date:  2015-09-17

3.  PI3K/AKT/PTEN Signaling as a Molecular Target in Leukemia Angiogenesis.

Authors:  Naoko Okumura; Hitomi Yoshida; Yasuko Kitagishi; Mutsumi Murakami; Yuri Nishimura; Satoru Matsuda
Journal:  Adv Hematol       Date:  2012-02-28

4.  In vivo monitoring of angiogenesis inhibition via down-regulation of mir-21 in a VEGFR2-luc murine breast cancer model using bioluminescent imaging.

Authors:  Dongliang Zhao; Yingfeng Tu; Lin Wan; Lihong Bu; Tao Huang; Xilin Sun; Kai Wang; Baozhong Shen
Journal:  PLoS One       Date:  2013-08-08       Impact factor: 3.240

5.  Endothelial hypoxic metabolism in carcinogenesis and dissemination: HIF-A isoforms are a NO metastatic phenomenon.

Authors:  Cristina Branco-Price; Colin E Evans; Randall S Johnson
Journal:  Oncotarget       Date:  2013-12

6.  NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis.

Authors:  Pengfei Yu; Liang Ye; Hongbo Wang; Guangying Du; Jianzhao Zhang; Yanhua Zuo; Jinghai Zhang; Jingwei Tian
Journal:  PLoS One       Date:  2014-12-31       Impact factor: 3.240

7.  Propranolol Participates in the Treatment of Infantile Hemangioma by Inhibiting HUVECs Proliferation, Migration, Invasion, and Tube Formation.

Authors:  Weili Yuan; Xukai Wang
Journal:  Biomed Res Int       Date:  2021-01-27       Impact factor: 3.411

Review 8.  Diagnostic and therapeutic strategy and the most efficient prognostic factors of breast malignant fibrous histiocytoma.

Authors:  Si-Qi Qiu; Xiao-Long Wei; Wen-He Huang; Ming-Yao Wu; Yun-Sheng Qin; Yang-Kang Li; Guo-Jun Zhang
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

9.  SHARP1 suppresses angiogenesis of endometrial cancer by decreasing hypoxia-inducible factor-1α level.

Authors:  Yun Liao; Wen Lu; Qi Che; Tingting Yang; Haifeng Qiu; Huijuan Zhang; Xiaoying He; Jingyun Wang; Meiting Qiu; Yingfen Zou; Wei Gu; Xiaoping Wan
Journal:  PLoS One       Date:  2014-06-11       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.